The Body's Own Cannabis-Like Chemical Causes Fewer Cognitive Problems Than THC in Monkeys

In squirrel monkeys, THC impaired learning, memory, attention, and cognitive flexibility in a dose-dependent manner, while stabilized forms of the body's own cannabinoid anandamide had minimal cognitive effects.

Kangas, Brian D et al.·The Journal of pharmacology and experimental therapeutics·2016·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-01190Animal StudyPreliminary Evidence2016RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Using touchscreen cognitive tests in squirrel monkeys, researchers compared THC with anandamide (the brain's own cannabinoid) and drugs that boost anandamide levels.

THC produced clear, dose-related impairments across multiple cognitive domains. The order of vulnerability was: discriminative capability was most sensitive, followed by learning, cognitive flexibility, and then short-term memory.

Anandamide alone and the FAAH inhibitor URB597 (which raises natural anandamide levels) had no effect on any cognitive test. Even when anandamide was stabilized by FAAH inhibition to prevent its rapid breakdown, cognitive effects were minimal, limited to some short-term memory disruption in some subjects at high doses.

All drugs left motivation unaffected, suggesting the cognitive impairments from THC are not simply due to reduced willingness to perform.

Key Numbers

THC impaired all four cognitive domains dose-dependently. Anandamide alone: no effects. URB597 alone: no effects. Anandamide + URB597: minimal effects, limited to short-term memory in some subjects. Motivation was unaffected by all drugs.

How They Did This

Battery of five touchscreen cognitive tests in squirrel monkeys: learning (repeated acquisition), cognitive flexibility (discrimination reversal), short-term memory (delayed matching-to-sample), attention (psychomotor vigilance), and motivation (progressive ratio). Multiple cannabinoid drugs tested with rimonabant antagonism to confirm CB1 mediation.

Why This Research Matters

This study suggests that therapeutics based on boosting the body's own endocannabinoid system (via FAAH inhibition) might provide medicinal benefits without the cognitive side effects of THC. This is a critical distinction for developing cannabinoid-based medicines.

The Bigger Picture

The endocannabinoid system is an attractive therapeutic target, but THC's cognitive side effects limit its clinical utility. The finding that boosting endocannabinoid tone through enzyme inhibition preserves cognition while still activating cannabinoid pathways is a key insight for drug development.

What This Study Doesn't Tell Us

Small number of subjects typical for primate studies. Squirrel monkey cognition may not directly translate to humans. Anandamide was given exogenously rather than generated endogenously. The specific FAAH inhibitor URB597 has since been shown to have limitations in clinical translation.

Questions This Raises

  • ?Would FAAH inhibitors preserve cognition while still providing pain relief or anti-anxiety effects?
  • ?Does the lack of cognitive effects from endocannabinoid enhancement translate to humans?

Trust & Context

Key Stat:
Boosting natural anandamide caused no cognitive impairment, unlike THC
Evidence Grade:
Primate cognitive battery with multiple drug comparisons and antagonist confirmation. Strong preclinical evidence but limited sample size.
Study Age:
Published in 2016. FAAH inhibitor drug development has continued but with setbacks, including a serious adverse event in a French clinical trial.
Original Title:
Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.
Published In:
The Journal of pharmacology and experimental therapeutics, 357(1), 125-33 (2016)
Database ID:
RTHC-01190

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Does THC affect all types of thinking equally?

No. In monkeys, THC was most disruptive to discriminative ability, moderately affected learning and flexibility, and had the least impact on short-term memory. Motivation was unaffected.

Could cannabis medicines be made without cognitive side effects?

This study suggests yes. Drugs that boost the body's natural endocannabinoids (rather than adding THC) preserved cognitive function in monkeys while still activating cannabinoid pathways.

Read More on RethinkTHC

Cite This Study

RTHC-01190·https://rethinkthc.com/research/RTHC-01190

APA

Kangas, Brian D; Leonard, Michael Z; Shukla, Vidyanand G; Alapafuja, Shakiru O; Nikas, Spyros P; Makriyannis, Alexandros; Bergman, Jack. (2016). Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.. The Journal of pharmacology and experimental therapeutics, 357(1), 125-33. https://doi.org/10.1124/jpet.115.228189

MLA

Kangas, Brian D, et al. "Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.." The Journal of pharmacology and experimental therapeutics, 2016. https://doi.org/10.1124/jpet.115.228189

RethinkTHC

RethinkTHC Research Database. "Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a B..." RTHC-01190. Retrieved from https://rethinkthc.com/research/kangas-2016-comparisons-of-9tetrahydrocannabinol-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.